Nanobodies®: new ammunition to battle viruses.

Autores
Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; Depla, Erik; Saelens, Xavier
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity.
Fil: Vanlandschoot, Peter. No especifíca;
Fil: Stortelers, Catelijne. No especifíca;
Fil: Beirnaert, Els. No especifíca;
Fil: Ibañez, Lorena Itatí. University of Ghent; Bélgica. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Schepens, Bert. University of Ghent; Bélgica
Fil: Depla, Erik. No especifíca;
Fil: Saelens, Xavier. University of Ghent; Bélgica
Materia
ANTIVIRAL
CAMELIDAE
HEAVY CHAIN-ONLY ANTIBODY
NANOBODY
VHH
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/194326

id CONICETDig_dcfde1f9531589e5b5d2015a23c91df8
oai_identifier_str oai:ri.conicet.gov.ar:11336/194326
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Nanobodies®: new ammunition to battle viruses.Vanlandschoot, PeterStortelers, CatelijneBeirnaert, ElsIbañez, Lorena ItatíSchepens, BertDepla, ErikSaelens, XavierANTIVIRALCAMELIDAEHEAVY CHAIN-ONLY ANTIBODYNANOBODYVHHhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1https://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity.Fil: Vanlandschoot, Peter. No especifíca;Fil: Stortelers, Catelijne. No especifíca;Fil: Beirnaert, Els. No especifíca;Fil: Ibañez, Lorena Itatí. University of Ghent; Bélgica. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Schepens, Bert. University of Ghent; BélgicaFil: Depla, Erik. No especifíca;Fil: Saelens, Xavier. University of Ghent; BélgicaElsevier Science2011-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/194326Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; et al.; Nanobodies®: new ammunition to battle viruses.; Elsevier Science; Antiviral Research; 92; 3; 12-2011; 389-4070166-3542CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2011.09.002info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0166354211004402info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:54:52Zoai:ri.conicet.gov.ar:11336/194326instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:54:53.095CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Nanobodies®: new ammunition to battle viruses.
title Nanobodies®: new ammunition to battle viruses.
spellingShingle Nanobodies®: new ammunition to battle viruses.
Vanlandschoot, Peter
ANTIVIRAL
CAMELIDAE
HEAVY CHAIN-ONLY ANTIBODY
NANOBODY
VHH
title_short Nanobodies®: new ammunition to battle viruses.
title_full Nanobodies®: new ammunition to battle viruses.
title_fullStr Nanobodies®: new ammunition to battle viruses.
title_full_unstemmed Nanobodies®: new ammunition to battle viruses.
title_sort Nanobodies®: new ammunition to battle viruses.
dc.creator.none.fl_str_mv Vanlandschoot, Peter
Stortelers, Catelijne
Beirnaert, Els
Ibañez, Lorena Itatí
Schepens, Bert
Depla, Erik
Saelens, Xavier
author Vanlandschoot, Peter
author_facet Vanlandschoot, Peter
Stortelers, Catelijne
Beirnaert, Els
Ibañez, Lorena Itatí
Schepens, Bert
Depla, Erik
Saelens, Xavier
author_role author
author2 Stortelers, Catelijne
Beirnaert, Els
Ibañez, Lorena Itatí
Schepens, Bert
Depla, Erik
Saelens, Xavier
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv ANTIVIRAL
CAMELIDAE
HEAVY CHAIN-ONLY ANTIBODY
NANOBODY
VHH
topic ANTIVIRAL
CAMELIDAE
HEAVY CHAIN-ONLY ANTIBODY
NANOBODY
VHH
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity.
Fil: Vanlandschoot, Peter. No especifíca;
Fil: Stortelers, Catelijne. No especifíca;
Fil: Beirnaert, Els. No especifíca;
Fil: Ibañez, Lorena Itatí. University of Ghent; Bélgica. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Schepens, Bert. University of Ghent; Bélgica
Fil: Depla, Erik. No especifíca;
Fil: Saelens, Xavier. University of Ghent; Bélgica
description In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies¯. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity.
publishDate 2011
dc.date.none.fl_str_mv 2011-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/194326
Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; et al.; Nanobodies®: new ammunition to battle viruses.; Elsevier Science; Antiviral Research; 92; 3; 12-2011; 389-407
0166-3542
CONICET Digital
CONICET
url http://hdl.handle.net/11336/194326
identifier_str_mv Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Ibañez, Lorena Itatí; Schepens, Bert; et al.; Nanobodies®: new ammunition to battle viruses.; Elsevier Science; Antiviral Research; 92; 3; 12-2011; 389-407
0166-3542
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2011.09.002
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0166354211004402
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269311996002304
score 13.13397